ADReCS

Pharmaceutical Information

Drug Name	Nicotine
Drug ID	BADD_D01564
Description	Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke.
Indications and Usage	For the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.
Marketing Status	approved
ATC Code	N07BA01
DrugBank ID	DB00184
KEGG ID	D03365
MeSH ID	D009538
PubChem ID	89594
TTD Drug ID	D0T8GD
NDC Product Code	17205-601; 58316-010; 11673-195; 11673-879; 37808-900; 37808-948; 43598-447; 59450-003; 59779-443; 70000-0115; 0536-1107; 70677-0030; 52922-001; 58316-009; 75877-0002; 11822-3627; 11822-4975; 21130-820; 37808-533; 37808-658; 43598-448; 49035-195; 55910-313; 66715-9802; 66715-9805; 66715-9806; 70000-0114; 28663-009; 58316-006; 11673-727; 11673-881; 37808-682; 0135-0196; 37808-711; 37808-739; 49035-196; 53329-192; 59450-002; 60429-443; 60429-445; 62011-0351; 63868-734; 70677-0032; 60429-444; 0363-0455; 0363-0457; 66715-9804; 68016-288; 28663-010; 58316-011; 11822-4973; 37808-753; 43598-446; 0009-5401; 50090-1148; 53329-193; 68016-289; 0536-1108; 58316-008; 29485-5271; 50090-2860; 63981-124; 66715-9803; 68196-194; 0536-1106; 61252-3005; 50090-1697; 59450-001; 63981-190; 70677-0031; 0135-0194; 0135-0195; 49035-782; 49348-788; 50090-2837; 59779-445; 62011-0350; 63868-735; 66715-9801; 68016-290; 69842-828; 50392-101; 55742-003; 11673-971; 11822-4974; 37808-707; 37808-849; 50090-6383; 55741-449; 59779-448; 0363-0451; 62011-0349; 81870-001; 11673-269; 11673-424; 21130-269; 43598-445; 53329-191; 69842-605; 70000-0113; 58316-007; 11673-194; 11673-196; 29485-5270; 37808-383; 37808-911; 49035-194; 0009-5400
UNII	6M3C89ZY6R
Synonyms	Nicotine \| Nicotine Bitartrate \| Nicotine Tartrate

Chemical Information

Molecular Formula	C10H14N2
CAS Registry Number	54-11-5; 22083-74-5
SMILES	CN1CCCC1C2=CN=CC=C2
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Tooth disorder	07.09.05.001	-	-	-
Tooth erosion	07.09.05.002	0.000627%		-
Tooth loss	07.09.09.001; 12.01.17.026	0.000627%		-
Toothache	07.09.06.001	-	-
Toxic epidermal necrolysis	10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008	0.000627%
Tremor	17.01.06.002	0.004200%
Trismus	15.05.04.004; 17.01.03.004	-	-
Unresponsive to stimuli	17.02.05.031	0.001567%		-
Urticaria	10.01.06.001; 23.04.02.001	0.008713%
Vaginal discharge	21.08.02.002	0.001254%
Vaginal haemorrhage	21.08.01.001; 24.07.03.005	0.001881%
Vasodilatation	23.06.05.006; 24.03.02.003	0.000940%		-
Vein disorder	24.03.02.015	-	-	-
Vertigo	04.04.01.003; 17.02.12.002	0.003260%
Vision blurred	06.02.06.007; 17.17.01.010	-	-
Visual impairment	06.02.10.013	0.003072%		-
Vomiting	07.01.07.003	0.017802%
Weight increased	13.15.01.006	-	-
Wheezing	22.03.01.009	0.001692%
Withdrawal syndrome	08.06.02.012; 19.07.06.023	0.005579%		-
Mobility decreased	08.01.03.030; 15.03.05.023; 17.02.05.018	0.000627%		-
Energy increased	08.01.03.017	0.000627%		-
Deafness unilateral	04.02.01.011	0.000940%		-
Hypoacusis	04.02.01.006	0.001379%
Application site vesicles	08.02.01.009; 12.07.01.009; 23.03.01.009	0.002758%		-
Application site inflammation	08.02.01.024; 12.07.01.024	-	-	-
Osteopenia	14.04.04.004; 15.02.03.003	0.000627%		-
Emotional distress	19.04.02.008	-	-	-
Muscle tightness	15.05.03.007	0.000627%		-
Application site urticaria	08.02.01.028; 10.01.06.002; 12.07.01.028; 23.04.02.002	0.003072%		-

The 11th Page First Pre 11 12 13 14 Next Last Total 14 Pages